medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2006, Number 1

<< Back Next >>

Acta Med 2006; 4 (1)

Human papillomavirus, cancer of the cervix and vaccination

Benítez-Bribiesca L

Language: Spanish
References: 23
Page: 51-55
PDF size: 60.70 Kb.


Text Extraction

No abstract


REFERENCES

  1. Castellsagué S, Bosch FX, Muñoz N et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105-1112.

  2. zur Hausen H. Papillomaviruses infections: a major cause of human cancers. Biochem Biophys Acta 1996; 1288: F55-F78.

  3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2002; 2: 342-350.

  4. Meisels A et al. Human papillomavirus infection of the cervix: the atypical condyloma. Acta Cytol 1976; 25: 7-16.

  5. Herrera L, Benítez-Bribiesca L, Mohar A, Ostrosky-Wegman P. The role of infections diseases in human carcinogenesis. Envir & Mol Mutagen 2005; 45:248-303.

  6. Mohar A, Lazcano E, Gariglio P. y cols. Carcinoma cervicouterino. En: Diez Problemas Relevantes de Salud en México. Eds. Juan Ramón de la Fuente y Jaime Sepúlveda Amor. Ed. Fondo de Cultura Económica. ISBN 968-16-6114-1. pp. 187-208.

  7. Gross FS, Benítez-Bribiesca L, Nindl I et al. The Association of Human Papillomavirus Type 16 E6 and E7 Antibodies with Stage of Cervical Cancer. Gynecol Oncol 1996; 61: 73-78.

  8. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: 412-420.

  9. Berumen J, Ordoñez RM, Lazcano E, Salmeron J et al. Asian-American variants of Human Papillomavirus 16 and risk for cervical cancer: A case-control study. J Natl Cancer Inst 2001; 93: 1325-1330.

  10. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999; 30: 269-274.

  11. Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-3963.

  12. Embers ME, Budgeon LR, Pickel M et al. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002; 76: 9798-9805.

  13. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004; 35: 971-982.

  14. Zhou J, Sun XY, Stenzel DJ et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257.

  15. Villa LL, Costa RLR, Petta CA, Andrade RP et al. Prophylactic quadrivalent human papillomavirus (types 6, 11,16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.

  16. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-1765.

  17. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: Promises and Challenges. The Oncologist 2005; 10: 528-538.

  18. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-1527.

  19. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005; 32(Suppl 1): S72-S81.

  20. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des 2005; 11: 3485-3500.

  21. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-indsgfuced tumors. J Immunol 2005; 175: 7297-7302.

  22. Lowndes CM. Vaccines for cervical cancer. Epidemiol Infect 2006; 134: 1-12.

  23. Steinbrook R. The Potential of Human Papillomavirus Vaccines. N Eng J Med 2006; 354: 1109-1112.




2020     |     www.medigraphic.com